Publish in this journal
Journal Information
Vol. 64. Issue S2.
Problemas relevantes en cardiología 2010
Pages 10-18 (July 2011)
(Spanish Only)
Share
Share
Download PDF
More article options
Vol. 64. Issue S2.
Problemas relevantes en cardiología 2010
Pages 10-18 (July 2011)
(Spanish Only)
Full text access
Papel de la resonancia magnética en la evaluación de las valvulopatías
Magnetic Resonance Imaging in the Assessment of Valvular Heart Disease
Visits
1649
Pastora Gallegoa
a Unidad de Técnicas Diagnósticas de Imagen, Servicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, España
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

Aunque la ecocardiografía Doppler continúa siendo la modalidad de imagen más utilizada en la evaluación de la enfermedad valvular, esta técnica presenta algunas limitaciones que pueden reducir la calidad de los estudios y dificultar la interpretación de los resultados. La resonancia magnética cardiaca puede llegar a ser superior a la ecocardiografía en algunos aspectos, que incluyen la valoración de las dimensiones, los volúmenes, la función y la masa ventriculares, la cuantificación de las insuficiencias valvulares y el estudio de áreas de fibrosis en el miocardio y de las estructuras extracardiacas. Se utiliza para ello una serie de secuencias de pulso, creadas para adquirir información sobre aspectos específicos de la caracterización tisular y de los flujos transvalvulares. Este artículo de divulgación general se centra en la utilidad clínica de la resonancia magnética en el diagnóstico de la enfermedad valvular y revisa cómo se integran los datos obtenidos mediante resonancia magnética cardiaca en los algoritmos de manejo clínico de los pacientes con lesiones valvulares significativas.

Palabras clave:
Resonancia magnética cardiaca
Valvulopatías
Insuficiencias valvulares
Estenosis valvulares

Although Doppler echocardiography remains the most frequently used imaging modality for assessing valvular heart disease, the technique has a number of limitations that could affect the quality of imaging studies and make the results difficult to interpret. Cardiac magnetic resonance (CMR) imaging could be superior to echocardiography in a number of ways: for example, for assessing ventricular dimensions, volumes, function and mass, for quantifying valvular regurgitation, and for investigating areas of myocardial fibrosis and extracardiac structures. In carrying out these tasks, CMR uses a variety of pulse sequences that are specially created to obtain information on specific tissue characteristics or on particular aspects of blood flow through heart valves. This general review article focuses on the usefulness of CMR in the clinical diagnosis of valvular heart disease and reviews how the data acquired using the technique can be incorporated into algorithms for the clinical management of patients with significant valvular heart lesions.

Keywords:
Cardiac magnetic resonance
Valvular heart disease
Valve regurgitation
Valve stenosis
Full text is only aviable in PDF
Bibliografía
[1]
Burden of valvular heart disease: a population based study. Lancet. 2006; 368:1005-11.
[2]
Aortic regurgitation: assessment with 64-section CT. Radiology. 2000; 245:111-21.
[3]
When should Doppler determined valve area be better than the Gorlin formula?. Variation in hydraulic constants in low flow states. J Am Coll Cardiol. 1987; 9:1294-305.
[4]
Quantification of aortic valve stenosis in MRI: comparison of steady state free precession and fast low angle shot sequences. Eur Radiol. 2007; 17:1284-90.
[5]
Valvular heart disease: what does cardiovascular MRI add?. Eur Radiol. 2008; 18:197-208.
[6]
Ventricular volume and mass by CMR. J Cardiovasc Magn Reson. 2002; 4:507-13.
[7]
Assessment of functional anatomy of the mitral valve in patients with mitral regurgitation with cine magnetic resonance imaging: comparison withtransesophageal echocardiography and surgical results. Eur Radiol. 2007; 17:3189-98.
[8]
Tumors of the cardiac valves: imaging findings in magnetic resonance imaging, electron beam computed tomography and echocardiography. Eur Radiol. 2000; 10:443-9.
[9]
How we perform delayed enhancement imaging. J Cardiovasc Magn Reson. 2003; 5:505-14.
[10]
Magn Reson Imaging Clin North Am. 1999; 7:699-715.
[11]
Flow measurement by magnetic resonance: a unique asset worth optimizing. J Cardiovasc Magn Reson. 2007; 9:1-6.
[12]
Phase contrast ultrashort TE: a more reliable technique for measurement of high velocity turbulent stenotic jets. Magn Res Med. 2009; 62:626-36.
[13]
Cardiovsacular magnetic resonance imaging for valvular hear disease. Technique and validation. Circulation. 2009; 119:468-78.
[14]
Evaluation of aortic stenosis by cardiovascular magnetic resonance imaging: comparison with established routine clinical techniques. Heart. 2004; 90:893-901.
[15]
imaging of valvular heart disease: display and imaging parameters affect the size of the signal void caused by valvular regurgitation. AJR Am J Roentgenol. 1990; 155:723-7.
[16]
Towards comprenhensive assessment of mitral regurgitation using cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008; 10:61-8.
[17]
2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 2008;52:e1-142.
[18]
Quantitative evaluation of aortic regurgitation in asymptomatic patients using CMR predicts long-term outcome. Heart Lung Circ. 2009; 18(Suppl 12):S5-6.
[19]
Aortic root measurement by cardiovascular magnetic resonance: specification of planes and lines of measurement and corresponding normal values. Circ Cardiovasc Imaging. 2008; 1:104-13.
[20]
Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualization of focal fibrosis. Heart. 2006; 92:1447-51.
[21]
Myocardial strain and torsion quantified by cardiovascular magnetic resonance tissue tagging studies in normal and impaired left ventricular function. J Am Coll Cardiol. 2006; 48:2002-11.
[22]
Role of magnetic resonance imaging in different ways of presentations of Ebstein's anomaly. J Cardiovasc Med. 2008; 9:628-30.
[23]
Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. Eur Respir J. 2002; 20:1519-24.
[24]
Assessment of Ebstein anomaly by cardiovascular magnetic resonance. Eur Heart J. 2007; 28Suppl:99.
[25]
Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. 1993; 329:593-9.
[26]
Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010; 31:2915-57.
[27]
Wald R, Redington AN, Pereira A, Provost YL, Paul NS, Oechslin EN, et al. Refining the assessment of pulmonary regurgitation in adults after tetralogy of Fallot repair: should we be measuring regurgitant fraction or regurgitant volume? Eur Heart J. 2009;30:356-1.
[28]
Pulmonary regurgitation in the late postoperative follow-up of tetralogy of Fallot. Volumetric quantification by nuclear magnetic resonance velocity mapping. Circulation. 1993; 88:2257-66.
[29]
Intra-observer and interobserver variability of biventricular function, volumes and mass in patients with congenital heart disease measured by CMR imaging. Int J Cardiovasc Imaging. 2010; 26:57-64.
[30]
Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation. 2007; 116:545-51.
[31]
Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation. 2006; 113:405-13.
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?